Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: A meta-analysis

Pancreas

Volumn 41, Issue 8, 2012, Pages 1195-1205

  Nissim, Sahar ^a   Idos, Gregory E ^a   Wu, Bechien ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cox2; cyclooxygenase 2; hTERT; intraductal papillary mucinous neoplasm; IPMN; kRas; marker; mucin; p53; pancreatic cancer; Sonic hedgehog; telomerase

Indexed keywords

CYCLOOXYGENASE 2; MUCIN 1; MUCIN 2; MUCIN 5AC; SONIC HEDGEHOG PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; EPITHELIUM CELL; GENE; GENETIC HETEROGENEITY; GENETIC MARKER; HISTOLOGY; HUMAN; IN SITU HYBRIDIZATION; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALIGNANT TRANSFORMATION; META ANALYSIS; PANCREAS CANCER; PANCREAS INTRADUCTAL PAPILLARY MUCINOUS TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SYSTEMATIC REVIEW; UPREGULATION;

ADENOCARCINOMA, MUCINOUS; ADENOMA; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; CELL TRANSFORMATION, NEOPLASTIC; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HEDGEHOG PROTEINS; HUMANS; MUCIN 5AC; MUCIN-1; MUCIN-2; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868303064     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182580fb4     Document Type: Article

References (82)

1. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977-987.
2. Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch. 1994;425(4):357-367.
3. Shimada K, Sakamoto Y, Sano T, et al. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas. 2006;32:281-287.
4. Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51(5): 717-722.
5. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg. 2001;234(3):313-321; discussion 312-321.
6. Kloppel G, Solcia E, Longnecker D, et al. Histological Typing of Tumours of the Exocrine Pancreas. World Health Organization International Histological Classification of Tumours. 2nd ed. Berlin: Springer-Verlag; 1996.
7. Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12(2):124-132.
8. Murakami Y, Uemura K, Hayashidani Y, et al. Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. J Gastrointest Surg. 2007;11(3):338-344.
9. Shin SH, Han DJ, Park KT, et al. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2010;34(4):776-783.
10. Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg. 1999;134(10):1131-1136.
11. Doi R, Fujimoto K, Wada M, et al. Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery. 2002;132(1):80-85.
12. Kitagawa Y, Unger TA, Taylor S, et al. Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg. 2003;7:12-18; discussion 18-19.
13. Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg. 2003;90(10):1244-1249.
14. Salvia R, Fernández-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239(5):678-685; discussion 677-685.
15. Takuma K, Kamisawa T, Anjiki H, et al. Predictors of malignancy and natural history of main-duct intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2011;40(3):371-375.
16. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36(3):666-676.
17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W264.
18. Luttges J, Zamboni G, Longnecker D, et al The immunohistochemical mucin expression pattern distinguishes different types of intraductal papillary mucinous neoplasms of the pancreas and determines their relationship to mucinous noncystic carcinoma and ductal adenocarcinoma. Am J Surg Pathol. 2001;25(7):942-948.
19. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15(10):1087-1095.
20. Terris B, Dubois S, Buisine MP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol. 2002;197(5):632-637.
21. Ito H, Endo T, Oka T, et al. Mucin expression profile is related to biological and clinical characteristics of intraductal papillary-mucinous tumors of the pancreas. Pancreas. 2005;30:e96-e102.
22. Moriya T, Kimura W, Semba S, et al. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int J Gastrointest Cancer. 2005;35(2):111-119.
23. Ueda M, Miura Y, Kunihiro O, et al. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT). Hepatogastroenterology. 2005;52(62):398-403.
24. Jang JY, Park YC, Song YS, et al. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas. J Hepatobiliary Pancreat Surg. 2009;16(5):668-674.
25. Cao W, Adley BP, Liao J, et al. Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. Hum Pathol. 2010;41:513-521.
26. Kanno A, Satoh K, Kimura K, et al. The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2006;33:391-396.
27. Z'graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997;226(4):491-498; discussion 498-500.
28. Mulligan NJ, Yang S, Andry C, et al. The role of p21ras in pancreatic neoplasia and chronic pancreatitis. Hum Pathol. 1999;30(6):602-610.
29. Paal E, Thompson LD, Przygodzki RM, et al. A clinicopathologic and immunohistochemical study of 22 intraductal papillary mucinous neoplasms of the pancreas, with a review of the literature. Mod Pathol. 1999;12(5):518-528.
30. Yoshizawa K, Nagai H, Sakurai S, et al. Clonality and K-ras mutation analyses of epithelia in intraductal papillary mucinous tumor and mucinous cystic tumor of the pancreas. Virchows Arch. 2002;441(5):437-443.
31. Mueller J, Gansauge S, Mattfeldt T. P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology. 2003;50(50):541-544.
32. Uemura K, Hiyama E, Murakami Y, et al. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours. Oncol Rep. 2003;10(2):277-283.
33. Kitago M, Ueda M, Aiura K, et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer. 2004;110(2):177-182.
34. Wada K, Takada T, Yasuda H, et al. Does ''clonal progression'' relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg. 2004;8:289-296.
35. Kobayashi N, Inamori M, Fujita K, et al. Characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms. J Hepatobiliary Pancreat Surg. 2008;15(2):169-177.
36. Schonleben F, Allendorf JD, Qiu W, et al. Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2008;36:168-172.
37. Schonleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2007;249:242-248.
38. Schonleben F, Qiu W, Remotti HE, et al. PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg. 2008; 393(3):289-296.
39. Chadwick B, Willmore-Payne C, Tripp S, et al. Histologic, immunohistochemical, and molecular classification of 52 IPMNs of the pancreas. Appl Immunohistochem Mol Morphol. 2009;17(1):31-39.
40. Fritz S, Fernandez-del Castillo C, Mino-Kenudson M, et al. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Ann Surg. 2009;249(3):440-447.
41. Biankin AV, Biankin SA, Kench JG, et al. Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut. 2002;50(6):861-868.
42. Jinfeng M, Kimura W, Sakurai F, et al. Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT. Int J Gastrointest Cancer. 2002;32:73-81.
43. Sasaki S, Yamamoto H, Kaneto H, et al. Differential roles of alterations of p53, p16, and SMAD4 expression in the progression of intraductal papillary-mucinous tumors of the pancreas. Oncol Rep. 2003; 10(1):21-25.
44. Nishikawa N, Kimura Y, Okita K, et al. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features. J Hepatobiliary Pancreat Surg. 2006;13(4):327-335.
45. Abe K, Suda K, Arakawa A, et al. Different patterns of p16INK4A and p53 protein expressions in intraductal papillary-mucinous neoplasms and pancreatic intraepithelial neoplasia. Pancreas. 2007;34:85-91.
46. Miyasaka Y, Nagai E, Yamaguchi H, et al. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2007;13:4371-4377.
47. Nodari F, Baiocchi GL, Salvi A, et al. Telomerase gene expression in intraductal papillary-mucinous tumors (IPMT): preliminary findings. Acta Biomed. 2003;74(suppl 2):59-64.
48. Hashimoto Y, Murakami Y, Uemura K, et al. Detection of human telomerase reverse transcriptase (hTERT) expression in tissue and pancreatic juice from pancreatic cancer. Surgery. 2008;143:113-125.
49. Hashimoto Y, Murakami Y, Uemura K, et al. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg. 2008;12(1):17-28; discussion 19-28.
50. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26(2):69-76.
51. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333-338.
52. Aoki T, Nagakawa Y, Tsuchida A, et al. Expression of cyclooxygenase-2 and vascular endothelial growth factor in pancreatic tumors. Oncol Rep. 2002;9(4):761-765.
53. Niijima M, Yamaguchi T, Ishihara T, et al. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer. 2002;94:1565-1573.
54. Jang KT, Lee KT, Lee JG, et al. Immunohistochemical expression of Sonic hedgehog in intraductal papillary mucinous tumor of the pancreas. Appl Immunohistochem Mol Morphol. 2007;15:294-298.
55. Liu MS, Yang PY, Yeh TS. Sonic hedgehog signaling pathway in pancreatic cystic neoplasms and ductal adenocarcinoma. Pancreas. 2007;34:340-346.
56. Satoh K, Kanno A, Hamada S, et al. Expression of Sonic hedgehog signaling pathway correlates with the tumorigenesis of intraductal papillary mucinous neoplasm of the pancreas. Oncol Rep. 2008;19(5):1185-1190.
57. Kim YS, Gum JR Jr. Diversity of mucin genes, structure, function, and expression. Gastroenterology. 1995;109(3):999-1001.
58. Ji Y, Lou WH, Jin DY, et al. A series of 64 cases of pancreatic cystic neoplasia from an institutional study of China. World J Gastroenterol. 2006;12(45):7380-7387.
59. Handra-Luca A, Flejou JF, Rufat P, et al. Human pancreatic mucinous cystadenoma is characterized by distinct mucin, cytokeratin and CD10 expression compared with intraductal papillary-mucinous adenoma. Histopathology. 2006;48:813-821.
60. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20(10): 1218-1249.
61. Harada N, Gansauge S, Gansauge F, et al. Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. Br J Cancer. 1997;76(3):299-305.
62. Bressac B, Galvin KM, Liang TJ, et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990;87(5):1973-1977.
63. Rodrigues NR, Rowan A, Smith ME, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990;87(19):7555-7559.
64. Uchino S, Noguchi M, Hirota T, et al. High incidence of nuclear accumulation of p53 protein in gastric cancer. Jpn J Clin Oncol. 1992;22(4):225-231.
65. Kawai A, Noguchi M, Beppu Y, et al. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor. Cancer. 1994;73(10):2499-2505.
66. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science. 2002;297(5581):565-569.
67. O'Hagan RC, Chang S, Maser RS, et al. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell. 2002;2(2):149-155.
68. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5(8):2018-2024.
69. Yip-Schneider MT, Barnard DS, Billings SD, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis. 2000;21(2):139-146.
70. Ito H, Duxbury M, Benoit E, et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 2004;64(20):7439-7446.
71. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003;2(1):1-7.
72. Morris JPt, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010;10(10):683-695.
73. Klimstra DS, Longnecker DS. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol. 1994;145(6):1547-1550.
74. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143(2):545-554.
75. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004;4(1):45-60.
76. Li Y, Bharti A, Chen D, et al. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol. 1998;18(12):7216-7224.
77. Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem. 2001;276(16):13057-13064.
78. Yamamoto M, Bharti A, Li Y, et al. Interaction of the DF3/MUC1 breast carcinomaYassociated antigen and beta-catenin in cell adhesion. J Biol Chem. 1997;272(19):12492-12494.
79. Spicer AP, Rowse GJ, Lidner TK, et al. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem. 1995;270(50): 30093-30101.
80. Sunamura M, Lefter LP, Duda DG, et al. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas. 2004;28:311-316.
81. Inoue H, Furukawa T, Sunamura M, et al. Exclusion of SMAD4 mutation as an early genetic change in human pancreatic ductal tumorigenesis. Genes Chromosomes Cancer. 2001;31(3):295-299.
82. Jamieson NB, Carter CR, McKay CJ, et al. Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res. 2011;17(10):3316-3331.